These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 8024262)

  • 1. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physostigmine treatment of progressive supranuclear palsy.
    Litvan I; Gomez C; Atack JR; Gillespie M; Kask AM; Mouradian MM; Chase TN
    Ann Neurol; 1989 Sep; 26(3):404-7. PubMed ID: 2802540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efaroxan, an alpha-2 antagonist, in the treatment of progressive supranuclear palsy.
    Rascol O; Sieradzan K; Peyro-Saint-Paul H; Thalamas C; Brefel-Courbon C; Senard JM; Ladure P; Montastruc JL; Lees A
    Mov Disord; 1998 Jul; 13(4):673-6. PubMed ID: 9686773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does the enhancement of cholinergic neurotransmission influence brain glucose kinetics and clinical symptomatology in progressive supranuclear palsy?
    Blin J; Mazetti P; Mazoyer B; Rivaud S; Ben Ayed S; Malapani C; Pillon B; Agid Y
    Brain; 1995 Dec; 118 ( Pt 6)():1485-95. PubMed ID: 8595479
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of physostigmine and scopolamine on the memory functions of chess players.
    Liljequist R; Mattila MJ
    Med Biol; 1979; 57(6):402-5. PubMed ID: 547122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of physostigmine on swallowing and oral motor functions in patients with progressive supranuclear palsy: A pilot study.
    Frattali CM; Sonies BC; Chi-Fishman G; Litvan I
    Dysphagia; 1999; 14(3):165-8. PubMed ID: 10341115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of physostigmine on spatial attention in patients with progressive supranuclear palsy.
    Kertzman C; Robinson DL; Litvan I
    Arch Neurol; 1990 Dec; 47(12):1346-50. PubMed ID: 2252453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Descriptive study of a serie of patients affected by progressive supranuclear palsy].
    Villanueva-Haba VE; Garcés M; de Vera A; Valero C; Burguera JA
    Rev Neurol; 2001 Jun 1-15; 32(11):1027-30. PubMed ID: 11562823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cholinergic systems in progressive supranuclear palsy.
    Warren NM; Piggott MA; Perry EK; Burn DJ
    Brain; 2005 Feb; 128(Pt 2):239-49. PubMed ID: 15649952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progressive supranuclear palsy].
    Tackmann W
    Schweiz Rundsch Med Prax; 1992 Dec; 81(51):1534-7. PubMed ID: 1470796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Progressive supranuclear palsy: neurological, neuropathological and neuropsychological aspects].
    Gómez-Haro C; Espert-Tortajada R; Gadea-Doménech M; Navarro-Humanes JF
    Rev Neurol; 1999 Nov 16-30; 29(10):936-56. PubMed ID: 10637844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An 81-year-old woman with progressive motor disturbance, extrapyramidal features, dementia, and oculomotor palsy].
    Urabe T; Mori H; Sumino S; Miwa H; Wakiya M; Shirai T; Takubo H; Mizuno Y
    No To Shinkei; 1998 Mar; 50(3):291-301. PubMed ID: 9566008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sleep abnormalities in progressive supranuclear palsy.
    Aldrich MS; Foster NL; White RF; Bluemlein L; Prokopowicz G
    Ann Neurol; 1989 Jun; 25(6):577-81. PubMed ID: 2742360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrospinal fluid acetylcholinesterase in progressive supranuclear palsy: reduced activity relative to normal subjects and lack of inhibition by oral physostigmine.
    Atack JR; Litvan I; Thal LJ; May C; Rapoport SI; Chase TN
    J Neurol Neurosurg Psychiatry; 1991 Sep; 54(9):832-5. PubMed ID: 1955905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinergic-dependent cognitive deficits in Parkinson's disease.
    Dubois B; Danzé F; Pillon B; Cusimano G; Lhermitte F; Agid Y
    Ann Neurol; 1987 Jul; 22(1):26-30. PubMed ID: 3631918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distal-proximal differences in limb apraxia in corticobasal degeneration but not progressive supranuclear palsy.
    Soliveri P; Piacentini S; Paridi D; Testa D; Carella F; Girotti F
    Neurol Sci; 2003 Oct; 24(3):213-4. PubMed ID: 14598093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrophy of the corpus callosum, cognitive impairment, and cortical hypometabolism in progressive supranuclear palsy.
    Yamauchi H; Fukuyama H; Nagahama Y; Katsumi Y; Dong Y; Konishi J; Kimura J
    Ann Neurol; 1997 May; 41(5):606-14. PubMed ID: 9153522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MK-801 impairs recognition memory in rhesus monkeys: comparison with cholinergic drugs.
    Ogura H; Aigner TG
    J Pharmacol Exp Ther; 1993 Jul; 266(1):60-4. PubMed ID: 8331575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Control of vertical components of gait during initiation of walking in normal adults and patients with progressive supranuclear palsy.
    Welter ML; Do MC; Chastan N; Torny F; Bloch F; du Montcel ST; Agid Y
    Gait Posture; 2007 Sep; 26(3):393-9. PubMed ID: 17126017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A case of progressive supranuclear palsy showing marked improvements of frontal hypoperfusion, as well as parkinsonism with amitriptyline].
    Asanuma M; Hirata H; Kondo Y; Ogawa N
    Rinsho Shinkeigaku; 1993 Mar; 33(3):317-21. PubMed ID: 8334795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.